CONTENTS

PERSPECTIVE


SHORT COMMUNICATION


ARTICLES

Esterase Inhibition Attribute of Grapefruit Juice Leading to a New Drug Interaction. Ping Li, Patrick S. Callery, Liang-Shang Gan, and Suresh K. Balani 1023

Valproic Acid Induces CYP3A4 and MDR1 Gene Expression by Activation of Constitutive Androstane Receptor and Pregnane X Receptor Pathways. Lukas Cerverny, Lucie Svecova, Eva Anzenbacherova, Radim Vrzal, Frantisek Staud, Zdenek Dvorak, Jitka Ulrichova, Pavel Anzenbacher, and Petr Pavek 1032

Biotransformation of 6-Methoxy-3-(3′,4′,5′-trimethoxy-benzoyl)-1H-indole (BPROL075), a Novel Antimicrotubule Agent, by Mouse, Rat, Dog, and Human Liver Microsomes. Hsien-Tsung Yao, Yu-Shan Wu, Yi-Wei Chang, Hsing-Pang Hsieh, Wei-Cheng Chen, Shih-Jung Lan, Chiung-Tong Chen, Yu-Sheng Chao, Ling Chang, Hsu-Yi Sun, and Teng-Kuang Yeh 1042

Possible Bioactivation Pathways of Lamotrigine. Wei Lu and Jack P. Uetrecht 1050

Effect of Perinatal Low Protein Diets on the Ontogeny of Select Hepatic Cytochrome P450 Enzymes and Cytochrome P450 Reductase in the Rat. Ganesh Cherala, Bernard H. Shapiro, and Anil P. D’mello 1057


Metabolism, Pharmacokinetics, and Excretion of a Nonpeptidic Substance P Receptor Antagonist, Ezlopitant, in Normal Healthy Male Volunteers: Characterization of Polar Metabolites by Chemical Derivatization with Dansyl Chloride. Chandra Prakash, John O’Donnell, and S. Cyrus Khojasteh-Bakht 1071

Identification of a Novel Glutathione Conjugate of Flutamide in Incubations with Human Liver Microsomes. Ping Kang, Deepak Dalvie, Evan Smith, Sue Zhou, and Alan Deese 1081

Intestinal First-Pass Metabolism via Carboxylesterase in Rat Jejunum and Ileum. Kenji Masaki, Mitsuru Hashimoto, and Teruko Imai 1089

Continued on next page

Isolation and Characterization of Polyspecific Mouse Organic Solute Carrier Protein 1 (mOscp1). Yasuna Kobayashi, Ayumi Tsuchiya, Tomofumi Hayashi, Noriko Kohyama, Masayuki Ohbayashi, and Toshinori Yamamoto ................................. 1239

ERRATUM

Correction to “Three-Dimensional Quantitative Structure-Activity Relationship Analysis of Human CYP51 Inhibitors”. S. Ekins, D. C. Mankowski, D. J. Hoover, M. P. Lawton, J. L. Treadway, and H. J. Harwood, Jr. ................................. 1246

Supplemental material is available online at http://dmd.aspetjournals.org.

About the cover: A diagram showing the relationship between % remaining and the therapeutic blood or plasma concentration of 171 marketed compounds in which in vivo DDI information was incorporated. See the article by Watanabe et al. in this issue on page 1232.